Project Oncology®

Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival.

This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive NSCLC. Tune in to discover how these therapeutics can benefit your patients.

This activity will enhance knowledge and competence in the management of HER2-positive breast cancer. Dr. William Gradishar and Dr. Peter Schmid engage in a lively discussion regarding the latest clinical data supporting novel investigational and approved therapies for the treatment of HER2-positive metastatic breast cancer. They also review strategies to manage adverse events associated with these therapies.

Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression.

This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.

The approval of PARP inhibitors for maintaining response to chemotherapy and in recurrent disease has improved outcomes for patients. Additionally, ongoing and conclusive studies are paving the way for PARP inhibitor use earlier in therapy.

This activity will discuss recent clinical trials and look at the paradigm shift with PARP inhibitors, specifically within the frontline setting. Also included is a look at how the approved and emerging PARP inhibitors can be used as monotherapy and in combination approaches.

While advanced non-small cell lung cancer remains incurable, innovations in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival.

This activity will discuss the new scientific and clinical data that have rapidly emerged on immunotherapies in the frontline setting that are leading to changes in the standard of care. Find out how these newer therapeutics will be utilized in everyday clinical practice.

Cervical cancer screening (CCS) methods include cytology alone, use of primary high-risk HPV testing alone, and co-testing. Regardless of the screening approach used, effective triage tests are needed to decide who among the presumptive positive women should receive further diagnostic evaluation. Unfortunately, current approaches to triage can complicate matters and the results can be more confusing than constructive.

Our discussion today will focus on how to address the unmet needs associated with current CCS triage options and the diagnostic benefits provided by p16/Ki-67 dual-staining cytology in CCS triage to alleviate diagnostic uncertainty within clinical practice.

The treatment of urothelial carcinoma, the most common type of bladder cancer, has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with metastatic urothelial cancer, as this activity explains.

The treatment of urothelial carcinoma, the most common type of bladder cancer, has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with metastatic urothelial cancer, as this activity explains.

The treatment of urothelial cancer has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with metastatic urothelial cancer, as this activity explains

Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease.

Here to walk us through a promising line of research with hopes of adding the first serum biomarker to the fight against non-small cell lung cancer is Dr. Tony Hu, professor and Weatherhead Presidential chair in Biotechnology Innovation at Tulane University Medical School.